Trial Profile

Phase I/II Study to Determine the Safety, Immunogenicity and Efficacy of the Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Aug 2023 According to a ISA Pharmaceuticals media release, Dr. Sonja Buschow is the Principal Investigators of the study.
31 Aug 2023 According to a ISA Pharmaceuticals media release, the study is The study is conducted in collaboration with investigators of the Gastroenterology & Hepatology department of the Erasmus MC in Rotterdam, The Netherlands.
31 Aug 2023 According to a ISA Pharmaceuticals media release, first patient has been dosed in this trial and dosing took place at the Liver Unit of the Erasmus Medical Center in Rotterdam.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com